Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.
暂无分享,去创建一个
[1] Michael Hawkins,et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Neil Desai,et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Brian Samuels,et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Gonzalez,et al. Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma , 2005 .
[5] P. Soon-Shiong,et al. A tolerability study of a cremophor free, nanoparticle albumin bound paclitaxel intravenously administered in Chinese patients with advanced solid tumor , 2005 .
[6] Michael Hawkins,et al. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.
[7] P. Soon-Shiong,et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol , 2005 .
[8] P. Soon-Shiong,et al. 601 Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: a pathway inhibited by Taxol , 2004 .
[9] N. Robert,et al. Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Gradishar,et al. Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Alex Sparreboom,et al. Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.
[12] J. Hornaday,et al. Cancer Facts & Figures 2004 , 2004 .
[13] J. Verweij,et al. Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.
[14] Patrick Soon-Shiong,et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] J Verweij,et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.
[16] J Verweij,et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.
[17] G. Bjarnason. Implications for cancer chemotherapy , 1995 .